ReviewToxins2021
Thrombolome and Its Emerging Role in Chronic Kidney Diseases.
Review in Toxins, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 27 citations in OpenAlex.
- New Advances in the Mechanisms and Therapeutic Strategies of Gut Microbiota in Regulating Glycolipid Metabolism to Combat Atherosclerosis.Journal of cardiovascular translational research · 2026Review
- Tryptophan metabolites clearance in hemodialyzed patients.Amino acids · 2026Article
- The Impact of Clinical Variables and Dialysis Modality on Kynurenine Pathway Enzymes Expression.International journal of molecular sciences · 2026Article
- The gut-heart axis: a review of the mechanisms and therapeutic prospects of gut microbiota and their metabolites in cardiovascular disease.Frontiers in cardiovascular medicine · 2026Review
- The Gut Microbiota-NLRP3 Inflammasome Axis in Chronic Heart Failure: Mechanisms Across Heart Failure Phenotypes and Therapeutic Perspectives.Journal of inflammation research · 2026Review
- Blood metabolites mediate causal inference studies on the effect of gut microbiota on the risk of vascular calcification.Journal of advanced research · 2026Article
- Causal relationship between chronic kidney disease, renal function, and venous thromboembolism: a bidirectional Mendelian randomization study.Renal failure · 2025Article
- Variability in Coagulation Profiles in Patients with Chronic Kidney Disease and Peripheral Artery Disease.Annals of vascular surgery · 2025Article
- Peritoneal dialysis-associated peritonitis, caused by superior mesenteric artery thrombosis with intestinal necrosis: a case report.CEN case reports · 2025Article
- Machine learning assisted breathomic approach for early-stage thoracic cancer detection.Frontiers in oncology · 2025Article
- Article
- Kynurenine Pathway after Kidney Transplantation: Friend or Foe?International journal of molecular sciences · 2024Review
- Hallmarks for Thrombotic and Hemorrhagic Risks in Chronic Kidney Disease Patients.International journal of molecular sciences · 2024Review
- Influence of the brain‑gut axis on neuroinflammation in cerebral ischemia‑reperfusion injury (Review).International journal of molecular medicine · 2024Review
- Incidence and risk factors of venous thromboembolism in kidney transplantation patients: a prospective cohort study.Journal of thrombosis and thrombolysis · 2024Article
- The in-vitro influence of urea concentration on thromboelastrography in patients with and without end stage renal disease.American journal of surgery · 2023Article
- Phenylacetylglutamine as a novel biomarker of type 2 diabetes with distal symmetric polyneuropathy by metabolomics.Journal of endocrinological investigation · 2023Article
- Tissue Factor, Thrombosis, and Chronic Kidney Disease.Biomedicines · 2022Review
- Proteomics: A Tool to Study Platelet Function.International journal of molecular sciences · 2021Review
- Causal associations between plasma metabolites and head and neck cancer: a bidirectional Mendelian randomization study.Brazilian journal of otorhinolaryngologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with chronic kidney disease (CKD) are at an increased risk of thromboembolic complications, including myocardial infarction, stroke, deep vein thrombosis, and pulmonary embolism. These complications lead to increased mortality. Evidence points to the key role of CKD-associated dysbiosis and its effect via the generation of gut microbial metabolites in inducing the prothrombotic phenotype. This phenomenon is known as thrombolome, a panel of intestinal bacteria-derived uremic toxins that enhance thrombosis via increased tissue factor expression, platelet hyperactivity, microparticles release, and endothelial dysfunction. This review discusses the role of uremic toxins derived from gut-microbiota metabolism of dietary tryptophan (indoxyl sulfate (IS), indole-3-acetic acid (IAA), kynurenine (KYN)), phenylalanine/tyrosine (p-cresol sulfate (PCS), p-cresol glucuronide (PCG), phenylacetylglutamine (PAGln)) and choline/phosphatidylcholine (trimethylamine N-oxide (TMAO)) in spontaneously induced thrombosis. The increase in the generation of gut microbial uremic toxins, the activation of aryl hydrocarbon (AhRs) and platelet adrenergic (ARs) receptors, and the nuclear factor kappa B (NF-κB) signaling pathway can serve as potential targets during the prevention of thromboembolic events. They can also help create a new therapeutic approach in the CKD population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.